A5014122300- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- PI3K/AKT/mTOR signaling in cancer
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer-related Molecular Pathways
- Lung Cancer Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- Cancer, Lipids, and Metabolism
- Genetic factors in colorectal cancer
- Platelet Disorders and Treatments
- Ancient Mediterranean Archaeology and History
- Historical, Religious, and Philosophical Studies
- Gene expression and cancer classification
- Estrogen and related hormone effects
- Pharmacogenetics and Drug Metabolism
- Classical Antiquity Studies
- Historical and Archaeological Studies
- Immunodeficiency and Autoimmune Disorders
Novartis (Switzerland)
2011-2024
National University Cancer Institute, Singapore
2013-2016
Aichi Cancer Center
2016
Memorial Sloan Kettering Cancer Center
2013-2016
BC Cancer Agency
2016
Breast International Group
2013-2016
German Breast group
2013-2016
Heinrich Heine University Düsseldorf
2016
Düsseldorf University Hospital
2016
Novartis (United States)
2011-2015
Abstract Background: PI3K pathway activation is a hallmark of hormone receptor-positive (HR+) BC cells resistant to endocrine therapy (ET). Preclinical and early clinical data suggest that combining the pan-PI3K inhibitor BUP (BKM120) with ET may provide benefits in this setting. BELLE-2 (NCT01610284) first randomized Phase III trial assess efficacy safety combined FULV HR+ advanced BC, including prospective analysis whether status measured archival tumor tissue ctDNA predictive benefit....
To evaluate and validate mRNA expression markers capable of identifying patients with ErbB2-positive breast cancer associated distant metastasis reduced survival.Expression 60 genes involved in biology was assessed by quantitative real-time PCR (qrt-PCR) 317 primary correlated clinical outcome data. Results were validated subsequently using two previously published publicly available microarray data sets different patient populations comprising 295 286 samples, respectively.Of the measured...
Abstract Introduction We investigated whether mRNA levels of E2F1, a key transcription factor involved in proliferation, differentiation and apoptosis, could be used as surrogate marker for the determination breast cancer outcome. Methods E2F1 other proliferation markers were measured by quantitative RT-PCR 317 primary patients from Stiftung Tumorbank Basel. Correlations to one another well estrogen receptor ERBB2 status clinical outcome investigated. Results validated further compared with...
Abstract Introduction Akt1, Akt2 and Akt3 kinases are downstream components of phosphoinositol 3-kinase derived signals from receptor tyrosine kinases, which influence cell growth, proliferation survival. overexpression amplification have been described in breast, ovarian pancreatic cancers. The present study was designed to investigate the prognostic significance activated Akt primary breast cancer its association with other tumour biomarkers. Methods Using a two-site...
BACKGROUND Treatment options for patients with non–small cell lung cancer (NSCLC) brain metastases are limited. Patupilone (EPO906), a blood‐brain barrier–penetrating, microtubule‐targeting, cytotoxic agent, has shown clinical activity in phase 1/2 studies NSCLC. This study evaluates the efficacy, pharmacokinetics, and safety of patupilone NSCLC metastases. METHODS Adult confirmed progressive received intravenously at 10 mg/m 2 every 3 weeks. The primary endpoint this multinomial 2‐stage...
New agents that are active in patients with metastatic colorectal cancer needed. Patupilone (EPO906; epothilone B) is a novel microtubule-stabilising agent. Patients advanced colon who progressed after prior treatment regimens received intravenous patupilone (6.5–10.0 mg m–2) once every 3 weeks by 20-min infusion (20MI), 24-h continuous (CI-1D) or 5-day intermittent 16-h (16HI-5D). Adverse events (AEs), dose-limiting toxicities (DLTs), pharmacokinetics and anti-tumour activity were assessed....
Abstract Introduction Gene expression profiling has been successfully used to classify breast cancer into clinically distinct subtypes, and predict the risk of recurrence treatment response. The aim this study was investigate whether gene profile (GEP) detected in a core biopsy (CB) is representative for entire tumor, since CB an important tool diagnosis. Moreover, we investigated performing CBs prior surgical excision could influence GEP respective tumor. Methods We quantified RNA 60...
Abstract Background: The PI3K/Akt/mTOR pathway is frequently activated in breast cancer (BC) and important for the oncogenic function of HER2. Buparlisib an oral pan-PI3K inhibitor that targets all 4 isoforms class I PI3K (α, β, γ, Δ). Preliminary clinical activity was observed with buparlisib patients (pts) advanced BC as a single agent, combination paclitaxel (Dirix et al. ESMO 2012) or trastuzumab (Pistilli 2012). Study design: NeoPHOEBE (NCT01816594) Phase II, randomized, double-blind,...
TPS650^ Background: The PI3K/Akt/mTOR pathway is commonly dysregulated in BC and linked to resistance endocrine therapy, including AIs. Buparlisib an oral inhibitor of class I PI3K isoforms (α, β, γ, δ), showing near complete tumor regression vivo model ER+ combination with fulvestrant. Preliminary clinical activity pts has been observed buparlisib as a single agent letrozole (Mayer et al. ASCO 2012). Methods: BELLE-2 (NCT01610284) BELLE-3 (NCT01633060) are 2 Ph III randomized, double-blind,...
Abstract Patupilone is a novel microtubule-targeting cytotoxic agent, which exerts its antitumor effect through microtubule stabilization. Pharmacokinetics, pharmacodynamics, and safety of warfarin when administered concomitantly with patupilone were investigated, activity was assessed. This phase I, two-center, drug–drug interaction study. In the core study, treatment consisted 20 mg orally (days 1 29) 10 mg/m2 i.v. 8 29). Patients benefiting from continued every 3 weeks (extension phase)...